PNPLA3 and hepatocellular carcinoma: Huang et al. reported that, using the Penn Medicine Biobank (PMBB) whole-exome sequence (WES) data (n > 40,000) and UK Biobank (UKB) WES data (n > 200,000), missense variants in TM6SF2 (E167K, L156P, P216L) were associated with an increased risk of clinically diagnosed and imaging-proven hepatic steatosis, independent of the PNPLA3 I48M risk allele and hepatitis B/C (p < 0.001), and that TM6SF2 E167K homozygotes had a significantly increased risk of steatotic liver disease (odds ratio [OR]: 5.38, p < 0.001), steatohepatitis (OR: 5.76, p < 0.05), and HCC (OR: 11.22, p < 0.0001).